Literature DB >> 10835634

TLR4 mutations are associated with endotoxin hyporesponsiveness in humans.

N C Arbour1, E Lorenz, B C Schutte, J Zabner, J N Kline, M Jones, K Frees, J L Watt, D A Schwartz.   

Abstract

There is much variability between individuals in the response to inhaled toxins, but it is not known why certain people develop disease when challenged with environmental agents and others remain healthy. To address this, we investigated whether TLR4 (encoding the toll-like receptor-4), which has been shown to affect lipopolysaccharide (LPS) responsiveness in mice, underlies the variability in airway responsiveness to inhaled LPS in humans. Here we show that common, co-segregating missense mutations (Asp299Gly and Thr399Ile) affecting the extracellular domain of the TLR4 receptor are associated with a blunted response to inhaled LPS in humans. Transfection of THP-1 cells demonstrates that the Asp299Gly mutation (but not the Thr399Ile mutation) interrupts TLR4-mediated LPS signalling. Moreover, the wild-type allele of TLR4 rescues the LPS hyporesponsive phenotype in either primary airway epithelial cells or alveolar macrophages obtained from individuals with the TLR4 mutations. Our findings provide the first genetic evidence that common mutations in TLR4 are associated with differences in LPS responsiveness in humans, and demonstrate that gene-sequence changes can alter the ability of the host to respond to environmental stress.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10835634     DOI: 10.1038/76048

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  533 in total

Review 1.  Toll-like receptor-mediated NF-kappaB activation: a phylogenetically conserved paradigm in innate immunity.

Authors:  G Zhang; S Ghosh
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

Review 2.  Toll receptors: a central element in innate immune responses.

Authors:  Thierry Vasselon; Patricia A Detmers
Journal:  Infect Immun       Date:  2002-03       Impact factor: 3.441

3.  A single nucleotide polymorphism in 3'-untranslated region contributes to the regulation of Toll-like receptor 4 translation.

Authors:  Kayo Sato; Atsutoshi Yoshimura; Takashi Kaneko; Takashi Ukai; Yukio Ozaki; Hirotaka Nakamura; Xinyue Li; Hiroyoshi Matsumura; Yoshitaka Hara; Yorimasa Ogata
Journal:  J Biol Chem       Date:  2012-06-01       Impact factor: 5.157

4.  Toll-like receptor signaling during myocardial ischemia.

Authors:  Tobias Eckle; Holger K Eltzschig
Journal:  Anesthesiology       Date:  2011-03       Impact factor: 7.892

5.  Toll-like receptor (TLR) 2 and 4 mutations in periodontal disease.

Authors:  M Folwaczny; J Glas; H-P Török; O Limbersky; C Folwaczny
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

Review 6.  Role of Toll-like receptors in pathogen recognition.

Authors:  S Janssens; R Beyaert
Journal:  Clin Microbiol Rev       Date:  2003-10       Impact factor: 26.132

7.  IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice.

Authors:  Pamela Gasse; Caroline Mary; Isabelle Guenon; Nicolas Noulin; Sabine Charron; Silvia Schnyder-Candrian; Bruno Schnyder; Shizuo Akira; Valérie F J Quesniaux; Vincent Lagente; Bernhard Ryffel; Isabelle Couillin
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

Review 8.  The genomic basis of cerebral palsy: a HuGE systematic literature review.

Authors:  M E O'Callaghan; A H MacLennan; E A Haan; G Dekker
Journal:  Hum Genet       Date:  2009-02-24       Impact factor: 4.132

Review 9.  Role of Toll-like receptor-4 in renal graft ischemia-reperfusion injury.

Authors:  Hailin Zhao; Jessica Santiváñez Perez; Kaizhi Lu; Andrew J T George; Daqing Ma
Journal:  Am J Physiol Renal Physiol       Date:  2014-02-12

10.  Toll like receptor 4 D299G associates with disease progression in Caucasian patients with chronic HBV infection: relationship with gender.

Authors:  Annarosa Cussigh; Carlo Fabris; Giovanna Fattovich; Edmondo Falleti; Sara Cmet; Davide Bitetto; Eleonora Bignulin; Pierluigi Toniutto
Journal:  J Clin Immunol       Date:  2012-10-24       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.